The Canadian Network of MS Clinics has posted a Q&A for patients with multiple sclerosis. Included are the group’s recommendations (see link below) for disease-modifying therapies (DMTs). Not immunosuppressant: Beta-interferons (Avonex, Betaseron/Extavia, Rebif, Plegridy), glatiramer acetate (Copaxone, Glatect), teriflunomide (Aubagio), and minocycline. Read More
Summary of epidemiology, testing and mortality rate; Canada and world statistics.
“It’s difficult to make predictions – especially about the future.” – Yogi Berra
A decade ago, Dr. Aaron Miller, Mount Sinai, New York, took a game swing at the crystal ball and wrote the article, “Multiple sclerosis: where will we be in 2020?” (Miller A. Mt Sinai J Med 2011;78:268-279). Read More
The Institute for Clinical and Economic Review (ICER), a drug pricing watchdog in the U.S., has ruled that novel oral migraine therapies have similar effectiveness but are not superior to triptans (5-HT 1B/1D agonists). Read More